导语：这一切的一切，都意味着百济这艘逐渐成长起来的巨轮，正在一步步驶离神州。就在泽布替尼在过去一年大卖26亿美元、带领百济神州科创板市值站稳3000亿大关、从而成为国内名副其实的“医药一哥”之时，长期跟踪这家中国创新药“领头羊”的从业者，也慢慢意识到一些变化正在悄然发生。比如，去年8月，上交所一条公告显示，百济神州上市主体公司的注册地已经从开曼变成了瑞士；比如，在最近的一场业绩沟通会上，曾经作为...
Source Link导语：这一切的一切，都意味着百济这艘逐渐成长起来的巨轮，正在一步步驶离神州。就在泽布替尼在过去一年大卖26亿美元、带领百济神州科创板市值站稳3000亿大关、从而成为国内名副其实的“医药一哥”之时，长期跟踪这家中国创新药“领头羊”的从业者，也慢慢意识到一些变化正在悄然发生。比如，去年8月，上交所一条公告显示，百济神州上市主体公司的注册地已经从开曼变成了瑞士；比如，在最近的一场业绩沟通会上，曾经作为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.